查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1860380

血浆疗法市场按技术、治疗领域、最终用户、供应来源、应用和分销管道划分－全球预测（2025-2032 年）

Plasma Therapy Market by Technology, Therapeutic Area, End User, Source, Application, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血浆疗法市场规模将达到 10.107 亿美元，复合年增长率为 12.66%。

关键市场统计数据
基准年 2024 3.8919亿美元
预计年份：2025年 4.3766亿美元
预测年份 2032 10.107亿美元
复合年增长率 (%) 12.66%

本文简要介绍了血浆疗法的临床发展历程、技术进步以及推动其在各种医疗机构中应用的关键因素。

随着临床医生、医疗设备开发商和医疗保健系统将生物策略与传统治疗方法结合，等离子体疗法已从实验性研究发展成为再生医学领域的重要组成部分。加工技术的进步和实证医学证据的不断积累，增强了临床医生对从皮肤再生到复杂肌肉骨骼修復等各种治疗手段的信心，并促使人们重新思考治疗路径和采购模式。

隔离技术、治疗方法多样化和分销创新的进步如何同时重塑临床应用路径和商业模式

血浆疗法领域正经历一系列变革，这些变革的驱动力包括技术改进、不断增长的实证医学证据以及供应链的现代化。在技​​术方面，分离和活化方法的进步催生了一系列差异化产品，包括混合释放型血浆、贫血小板血浆、富血小板纤维蛋白和富血小板血浆，每种产品都具有不同的操作特性、临床应用特征以及与医疗团队整合的要求。

评估 2025 年关税调整将对供应链和商业策略带来的压力，鼓励考虑近岸外包、采购多元化和总拥有成本 (TCO)。

美国将于2025年实施的关税政策，使全球医疗设备、耗材和生物处理试剂盒（血浆疗法流程的核心）的供应链面临新的检视。关税带来的成本压力迫使供应商和医疗机构重新评估其筹资策略，特别关注零件的在地采购、库存缓衝以及替代分销管道，以维持治疗流程的经济效益。为此，製造商正在加速关键耗材的近岸外包，并优先选择能够提供透明的原产地追踪和合规文件的供应商。

全面的細項分析揭示了差异化技术、治疗领域、终端用户、供应来源、应用和分销特征如何影响商业化优先事项。

细分市场分析揭示了不同技术、治疗领域、最终用户、供应来源、应用和分销管道所带来的独特机会和风险，每种情况都需要客製化的商业化策略。技术细分区分了混合释放、贫血小板血浆、富血小板纤维蛋白和富血小板血浆等平台，这些平台的应用取决于处理时间、特定适应症的临床证据以及与现有手术流程的兼容性。不同技术的患者选择标准和临床医生培训要求差异显着，从而导致不同的市场进入策略。

区域趋势和采用模式凸显了监管差异、临床实践差异和供应链基础设施如何驱动区域策略选择。

血浆疗法的区域发展趋势受到各主要地区监管方式、临床实践模式和供应链基础设施差异的影响。在美洲，公立和私立医疗机构的强大组合正在加速血浆疗法在美容、牙科和肌肉骨骼疾病领域的应用，而蓬勃发展的专科诊所和门诊手术中心生态系统也为此提供了支持。该地区的医保报销谈判和支付方合作对于更广泛的机构应用仍然至关重要，而监管政策的明确性将有助于临床试验和治疗方案的核准。

具有竞争力的企业策略强调平台差异化、临床伙伴关係和灵活的分销管道，以加速产品应用并建立临床医生的信任。

血浆疗法生态系统中主要企业的发展趋势反映了专业设备製造商、生技药品製剂加工商和综合临床服务提供者之间的相互作用。主要企业致力于透过投资自动化、封闭式系统处理和耗材设计来实现平台差异化，从而减少操作人员的差异性并简化通讯协定执行流程。同时，设备製造商与临床网路之间的策略联盟已成为一种有效机制，能够加速产生真实世界证据，并在不同的医疗环境中检验治疗流程。

为使证据产生、培训计画和弹性供应链与特定管道的商业化策略保持一致，提供切实可行的建议。

产业领导者应采取务实且以证据为导向的策略，平衡临床检验、供应链韧性和目标商业化。首先，优先进行与自身技术最具影响力的治疗细分领域相符的务实临床试验和真实世界证据研究，并确保研究设计能够捕捉到对临床医生和支付方都具有实际意义的结果。其次，建立多层次的培训项目，以促进门诊手术中心、医院、专科诊所和居家医疗机构等不同医疗机构的工作流程整合，从而最大限度地减少操作差异，并确保结果的可重复性。

我们采用严谨的混合调查方法，结合临床医生访谈、证据综合和同行检验，以提供可靠、可操作的研究结果。

本报告的调查方法融合了定性和定量方法，以确保获得可靠且多角度验证的见解。主要研究包括对门诊手术中心、医院、专科诊所和居家医疗机构的临床负责人、采购人员和分销合作伙伴进行深度访谈。研究探讨了采纳驱动因素、通讯协定偏好、供应链挑战和报销谈判，从而深入了解不同医疗保健机构的营运现况。

最终整合将临床证据、营运准备和供应链韧性纳入策略蓝图，以实现一致的实施并影响患者。

总之，血浆疗法处于生物学和程序医学的交叉领域，技术细节、临床证据和分销设计共同决定了其在现实世界中的影响。相关人员将严谨的证据收集与卓越的培训和供应链管理相结合，便可加速血浆疗法在各种治疗应用中的永续推广。此外，积极应对关税风险并确保通路灵活性的机构，能够减少商业性摩擦，并确保关键耗材的供应。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大高免疫血浆製品的应用范围，以因应 COVID-19 治疗策略中新出现的病毒变异株
  • 引入自动化血浆分离系统，以提高捐血处理能力并缩短处理时间
  • 将人工智慧演算法整合到预测性捐血者筛检中，以提高血浆品质
  • 开发病原体减少技术以确保康復者血浆疗法的安全性
  • 加强生技公司与血库之间的合作，以实现免疫球蛋白的大规模生产
  • 全球市场监管政策的演变使得新型血浆疗法的紧急使用授权成为可能。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按技术分類的血浆疗法市场

  • 混合释放速率
  • 血小板贫乏血浆
  • 富血小板纤维蛋白
  • 富血小板血浆

9. 按治疗区域分類的血浆疗法市场

  • 自体免疫疾病
  • 心血管修復
  • 皮肤科/美容医学
    • 毛髮再生
    • 疤痕矫正
    • 皮肤再生
  • 整形外科
    • 骨折癒合
    • 关节内注射
    • 肌腱修復
  • 创伤治疗
    • 糖尿病溃疡
    • 压疮
    • 静脉溃疡

第十章 依最终用户分類的血浆疗法市场

  • 门诊手术中心
  • 居家医疗环境
  • 医院
  • 专科诊所

第十一章 血浆疗法市场（依来源划分）

  • 同种异体移植
  • 自体

第十二章 按应用分類的血浆疗法市场

  • 美容护理
  • 牙科治疗
  • 肌肉骨骼损伤
  • 眼科治疗

第十三章 按分销管道分類的血浆疗法市场

  • 医院药房
  • 线上管道
    • 直接从製造商购买
    • 市场平台
  • 零售药房

第十四章 各地区血浆疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 按组别分類的血浆疗法市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国血浆疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • CSL Behring GmbH
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Biotest AG
    • Kedrion SpA
    • LFB SA
    • Bio Products Laboratory Ltd
    • ADMA Biologics, Inc.
    • Stichting Sanquin Bloedvoorziening
Product Code: MRR-DD0700E81E9A

The Plasma Therapy Market is projected to grow by USD 1,010.70 million at a CAGR of 12.66% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 389.19 million
Estimated Year [2025] USD 437.66 million
Forecast Year [2032] USD 1,010.70 million
CAGR (%) 12.66%

A concise introduction that frames plasma therapy's clinical maturation, technological improvements, and the operational factors driving adoption across care settings

Plasma therapy has traversed experimental curiosity to an established component of regenerative medicine portfolios, as clinicians, device developers, and health systems integrate biologic strategies alongside traditional interventions. Advances in processing technologies and evidence synthesis have elevated clinical confidence in procedures ranging from dermatologic rejuvenation to complex musculoskeletal repair, prompting a re-examination of care pathways and procurement models.

As regulatory frameworks mature and payer discussion increases, stakeholders must reconcile procedural efficacy with operational realities such as kit logistics, training, and clinic workflow integration. Consequently, early adopters who combine clinical rigor with robust supply chain planning and clinician education have accelerated acceptance in ambulatory surgical centers, specialty clinics, and hospital settings. Through this lens, the introduction sets the stage for a deeper exploration of the technological, therapeutic, and commercial inflection points that define the current landscape and near-term strategic choices.

How concurrent advances in separation technology, therapeutic diversification, and distribution innovation are reshaping clinical adoption pathways and commercial models

The landscape for plasma therapy is undergoing a set of transformative shifts driven by technological refinement, evidence accumulation, and supply chain modernization. On the technology front, advances in separation and activation methods have differentiated offerings such as Hybrid Releasate, Platelet-Poor Plasma, Platelet-Rich Fibrin, and Platelet-Rich Plasma, each presenting distinct handling characteristics, clinical profiles, and integration requirements for procedural teams.

Concurrently, therapeutic diversification has progressed beyond singular indications into a multi-specialty construct that includes autoimmune disorders, cardiovascular repair, dermatology and aesthetics, orthopedics, and wound healing. Within dermatology and aesthetics, modalities such as hair restoration, scar revision, and skin rejuvenation illustrate how procedural demand can vary by subtype. Orthopedic applications span fracture healing, joint injections, and tendon repair, while wound healing strategies address diabetic ulcers, pressure ulcers, and venous ulcers. These clinical expansions intersect with evolving end-user models, where ambulatory surgical centers, home care settings, hospitals, and specialty clinics adopt differentiated procurement and administration pathways. Additionally, distribution innovation-spanning hospital pharmacies, online channels including manufacturer direct and marketplace platforms, and retail pharmacies-reshapes how devices and biologic kits reach point of care. Together, these dynamics are raising expectations for cross-disciplinary evidence generation, standardized protocols, and interoperable supply chains that can support broader and more consistent application.

Assessing how tariff adjustments in 2025 pressure supply chains and commercial strategies, prompting nearshoring, sourcing diversification, and total cost of ownership thinking

The introduction of tariffs by the United States in 2025 has introduced renewed scrutiny on global supply chains for devices, disposables, and biologic processing kits central to plasma therapy workflows. Tariff-driven cost pressures have prompted suppliers and providers to reassess sourcing strategies, with a particular focus on component localization, inventory buffering, and alternate distribution channels to preserve procedural economics. In response, manufacturers have accelerated nearshoring initiatives for critical consumables and have prioritized suppliers with transparent origin tracing and compliant documentation.

Furthermore, tariffs have influenced procurement negotiations between hospitals, ambulatory surgical centers, and specialty clinics, shifting emphasis to total cost of ownership rather than unit price alone. Providers increasingly evaluate logistics overhead, customs clearance complexity, and product substitution risk when establishing vendor relationships. In parallel, research and development partners are exploring design changes that reduce dependence on tariff-exposed components, and commercial teams are expanding channel strategies to include manufacturer-direct online channels and regional distribution hubs. Taken together, these actions are reshaping commercial playbooks: organizations that proactively map tariff exposure, diversify supplier baselines, and incorporate flexible distribution models stand to reduce disruption and protect margins while maintaining consistent clinical availability.

Comprehensive segmentation insights revealing how differentiated technology, therapeutic, end-user, source, application, and distribution characteristics shape commercialization priorities

Segmentation insight reveals distinct opportunity and risk profiles across technology, therapeutic area, end user, source, application, and distribution channels, each demanding tailored commercialization tactics. Technology segmentation differentiates platforms such as Hybrid Releasate, Platelet-Poor Plasma, Platelet-Rich Fibrin, and Platelet-Rich Plasma, where adoption hinges on processing time, clinical evidence for specific indications, and compatibility with existing procedural workflows. Patient selection criteria and clinician training requirements vary meaningfully across these technologies, creating discrete go-to-market imperatives.

Therapeutic area segmentation highlights that autoimmune disorders, cardiovascular repair, dermatology and aesthetics, orthopedics, and wound healing each present unique regulatory, reimbursement, and clinical evidence pathways. Within dermatology and aesthetics, subareas like hair restoration, scar revision, and skin rejuvenation attract different provider types and patient expectations, whereas orthopedics' subcategories of fracture healing, joint injections, and tendon repair demand surgical integration and peri-procedural logistics. Wound healing subsegments such as diabetic ulcers, pressure ulcers, and venous ulcers require coordination with chronic care teams and long-term outcome tracking. End-user segmentation across ambulatory surgical centers, home care settings, hospitals, and specialty clinics influences purchasing cycles, training delivery modes, and stocking policies. Source segmentation between allogeneic and autologous options creates divergent regulatory and ethical considerations that affect consent workflows and inventory management. Application segmentation spanning cosmetic procedures, dental procedures, musculoskeletal injuries, and ophthalmology procedures underscores the need for specialized clinical protocols and targeted evidence generation. Finally, distribution channel segmentation including hospital pharmacies, online channels with manufacturer direct and marketplace platforms, and retail pharmacies defines access patterns and influences commercial partnerships. Recognizing these layered distinctions enables stakeholders to prioritize clinical programs, align sales coverage models, and tailor educational initiatives to the realities of each segment.

Regional dynamics and adoption patterns highlighting how regulatory variation, clinical practice differences, and supply chain infrastructure drive regional strategy choices

Regional dynamics in plasma therapy are shaped by regulatory approaches, clinical practice patterns, and supply chain infrastructure that differ across major geographies. In the Americas, a strong mix of private and public providers has accelerated adoption in cosmetic, dental, and musculoskeletal applications, supported by an active ecosystem of specialty clinics and ambulatory surgical centers. Reimbursement discussions and payer engagement in the region remain pivotal for broader institutional adoption, and regulatory clarity supports clinical trials and pathway approvals.

In Europe, Middle East & Africa, adoption reflects pronounced variability: established centers in Western Europe emphasize evidence-based integration into orthopedic and wound healing protocols, while pockets of innovation in the Middle East focus on aesthetic and dental applications backed by private investment. Across this geography, variations in regulatory timelines and procurement practices mean manufacturers must adopt regional regulatory strategies and flexible distribution models. In Asia-Pacific, rapid urbanization, expanding clinical capacity, and growing interest in minimally invasive regenerative procedures have driven demand in both metropolitan hospitals and specialty chains. However, the region also presents heterogeneity in reimbursement, clinician training infrastructure, and manufacturing capabilities, which necessitates nuanced market entry tactics and partnerships with local clinical champions. Across all regions, logistical resilience, clinician education, and locally relevant evidence generation remain the primary levers for sustainable uptake.

Competitive company strategies that emphasize platform differentiation, clinical partnerships, and distribution flexibility to accelerate adoption and build clinician trust

Key company dynamics in the plasma therapy ecosystem reflect an interplay between specialized device manufacturers, biologics processors, and integrated clinical service providers. Leading organizations have focused on platform differentiation through investments in automation, closed-system processing, and consumable design that reduces operator variability and streamlines protocol adherence. Meanwhile, strategic partnerships between device firms and clinical networks have emerged as an efficient mechanism to accelerate real-world evidence generation and to validate procedural workflows in diverse care settings.

On the commercial front, companies that combine product reliability with comprehensive training programs and robust post-market surveillance have consistently strengthened clinician trust. Distribution strategies are likewise evolving, with some firms emphasizing direct-to-clinic online channels to shorten time-to-procure while others leverage hospital pharmacy relationships to tap institutional purchasing processes. Finally, entrants that prioritize modular product architectures and regulatory alignment across jurisdictions reduce barriers for adoption and enable incremental market expansion through focused indication-by-indication rollouts. Collectively, these corporate strategies point to a competitive environment where execution excellence in clinical support, supply chain reliability, and evidence generation determines sustainable differentiation.

Actionable recommendations for leaders to align evidence generation, training programs, and resilient supply chains with channel-specific commercialization strategies

Industry leaders should adopt a pragmatic, evidence-centric playbook that balances clinical validation, supply chain resilience, and targeted commercialization. First, prioritize pragmatic clinical trials and real-world evidence studies that align with the highest-impact therapeutic subsegments for your technology, ensuring study designs capture outcomes meaningful to both clinicians and payers. Second, establish multi-tiered training programs that address workflow integration for ambulatory surgical centers, hospitals, specialty clinics, and home care settings to minimize procedural variability and support repeatable outcomes.

Third, optimize supply chain strategies by mapping tariff exposure, diversifying qualified suppliers for critical consumables, and expanding regional distribution hubs to reduce lead times. Fourth, tailor distribution models to channel realities: leverage hospital pharmacy relationships for institutional sales, scale manufacturer-direct online channels for specialty clinics, and evaluate marketplace platforms to reach broader retail or outpatient audiences. Fifth, design product portfolios that account for source preferences-balancing autologous offerings that emphasize patient-matched therapeutics with allogeneic options that prioritize standardization and scale. Finally, align commercial messaging to clinical evidence and health economics narratives that resonate with procurement decision-makers, emphasizing total cost of care and workflow efficiencies rather than unit price alone. Implementing these recommendations will improve resilience, adoption velocity, and alignment with clinical stakeholders.

A rigorous mixed-methods research approach combining clinician interviews, evidence synthesis, and expert validation to deliver credible and actionable insights

The research methodology underpinning this report blends qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research comprised in-depth interviews with clinical leaders, procurement heads, and distribution partners across ambulatory surgical centers, hospitals, specialty clinics, and home care providers. These interviews explored adoption drivers, protocol preferences, supply chain pain points, and reimbursement conversations, enabling a grounded understanding of operational realities across care settings.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory filings, clinical trial registries, and publicly available company documentation to map technology characteristics and evidence trajectories. Data triangulation combined primary interview themes with secondary evidence to validate patterns and identify areas of convergent insight. Additionally, subject-matter expert panels provided scenario testing for tariff impacts and distribution adaptations. Throughout, methodological rigor emphasized transparency of assumptions, reproducible interview guides, and quality control checks on synthesized findings to support credible, actionable outcomes for stakeholders.

A concluding synthesis that ties clinical evidence, operational readiness, and supply chain resilience into a strategic roadmap for consistent adoption and patient impact

In closing, plasma therapy occupies a pragmatic intersection between biologic science and procedural medicine, where technological nuance, clinical evidence, and distribution design collectively determine real-world impact. Stakeholders who couple rigorous evidence generation with operational excellence in training and supply chain management can accelerate sustainable adoption across a range of therapeutic applications. Moreover, organizations that proactively address tariff exposure and channel flexibility will reduce commercial friction and protect access to critical consumables.

Looking ahead, the maturation of standardized protocols, multi-center real-world studies, and interoperable distribution models will be central to unlocking broader institutional adoption. By focusing on clinically meaningful outcomes, aligning commercialization strategies with end-user realities, and investing in resilient supply chains, leaders can translate the promise of plasma therapy into consistent, high-quality patient care across regions and therapy areas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of hyperimmune plasma products targeting emerging viral variants in COVID-19 treatment strategies
  • 5.2. Adoption of automated plasmapheresis systems to enhance donor throughput and reduce processing times
  • 5.3. Integration of artificial intelligence algorithms for predictive donor screening to improve plasma quality
  • 5.4. Development of pathogen reduction technologies to ensure safety in convalescent plasma therapies
  • 5.5. Rising collaborations between biotech firms and blood banks for large-scale immunoglobulin production
  • 5.6. Regulatory evolution in global markets enabling emergency use authorization for novel plasma therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plasma Therapy Market, by Technology

  • 8.1. Hybrid Releasate
  • 8.2. Platelet-Poor Plasma
  • 8.3. Platelet-Rich Fibrin
  • 8.4. Platelet-Rich Plasma

9. Plasma Therapy Market, by Therapeutic Area

  • 9.1. Autoimmune Disorders
  • 9.2. Cardiovascular Repair
  • 9.3. Dermatology & Aesthetics
    • 9.3.1. Hair Restoration
    • 9.3.2. Scar Revision
    • 9.3.3. Skin Rejuvenation
  • 9.4. Orthopedics
    • 9.4.1. Fracture Healing
    • 9.4.2. Joint Injections
    • 9.4.3. Tendon Repair
  • 9.5. Wound Healing
    • 9.5.1. Diabetic Ulcers
    • 9.5.2. Pressure Ulcers
    • 9.5.3. Venous Ulcers

10. Plasma Therapy Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Plasma Therapy Market, by Source

  • 11.1. Allogeneic
  • 11.2. Autologous

12. Plasma Therapy Market, by Application

  • 12.1. Cosmetic Procedures
  • 12.2. Dental Procedures
  • 12.3. Musculoskeletal Injuries
  • 12.4. Ophthalmology Procedures

13. Plasma Therapy Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Channels
    • 13.2.1. Manufacturer Direct
    • 13.2.2. Marketplace Platforms
  • 13.3. Retail Pharmacies

14. Plasma Therapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Plasma Therapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Plasma Therapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. CSL Behring GmbH
    • 17.3.2. Grifols, S.A.
    • 17.3.3. Takeda Pharmaceutical Company Limited
    • 17.3.4. Octapharma AG
    • 17.3.5. Biotest AG
    • 17.3.6. Kedrion S.p.A.
    • 17.3.7. LFB S.A.
    • 17.3.8. Bio Products Laboratory Ltd
    • 17.3.9. ADMA Biologics, Inc.
    • 17.3.10. Stichting Sanquin Bloedvoorziening

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PLASMA THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA THERAPY MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PLASMA THERAPY MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PLASMA THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PLASMA THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PLASMA THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PLASMA THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PLASMA THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PLASMA THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PLASMA THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLASMA THERAPY MARKET SIZE, BY HYBRID RELEASATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA THERAPY MARKET SIZE, BY HYBRID RELEASATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA THERAPY MARKET SIZE, BY HYBRID RELEASATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA THERAPY MARKET SIZE, BY HYBRID RELEASATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA THERAPY MARKET SIZE, BY HYBRID RELEASATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA THERAPY MARKET SIZE, BY HYBRID RELEASATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-POOR PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-POOR PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-POOR PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-POOR PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-POOR PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-POOR PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH FIBRIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH FIBRIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH FIBRIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH FIBRIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH FIBRIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH FIBRIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA THERAPY MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLASMA THERAPY MARKET SIZE, BY CARDIOVASCULAR REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PLASMA THERAPY MARKET SIZE, BY CARDIOVASCULAR REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLASMA THERAPY MARKET SIZE, BY CARDIOVASCULAR REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PLASMA THERAPY MARKET SIZE, BY CARDIOVASCULAR REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLASMA THERAPY MARKET SIZE, BY CARDIOVASCULAR REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA THERAPY MARKET SIZE, BY CARDIOVASCULAR REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLASMA THERAPY MARKET SIZE, BY HAIR RESTORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PLASMA THERAPY MARKET SIZE, BY HAIR RESTORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLASMA THERAPY MARKET SIZE, BY HAIR RESTORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PLASMA THERAPY MARKET SIZE, BY HAIR RESTORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLASMA THERAPY MARKET SIZE, BY HAIR RESTORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PLASMA THERAPY MARKET SIZE, BY HAIR RESTORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLASMA THERAPY MARKET SIZE, BY SCAR REVISION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA THERAPY MARKET SIZE, BY SCAR REVISION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA THERAPY MARKET SIZE, BY SCAR REVISION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA THERAPY MARKET SIZE, BY SCAR REVISION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLASMA THERAPY MARKET SIZE, BY SCAR REVISION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA THERAPY MARKET SIZE, BY SCAR REVISION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLASMA THERAPY MARKET SIZE, BY SKIN REJUVENATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PLASMA THERAPY MARKET SIZE, BY SKIN REJUVENATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLASMA THERAPY MARKET SIZE, BY SKIN REJUVENATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PLASMA THERAPY MARKET SIZE, BY SKIN REJUVENATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLASMA THERAPY MARKET SIZE, BY SKIN REJUVENATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PLASMA THERAPY MARKET SIZE, BY SKIN REJUVENATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLASMA THERAPY MARKET SIZE, BY FRACTURE HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PLASMA THERAPY MARKET SIZE, BY FRACTURE HEALING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLASMA THERAPY MARKET SIZE, BY FRACTURE HEALING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PLASMA THERAPY MARKET SIZE, BY FRACTURE HEALING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLASMA THERAPY MARKET SIZE, BY FRACTURE HEALING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PLASMA THERAPY MARKET SIZE, BY FRACTURE HEALING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLASMA THERAPY MARKET SIZE, BY JOINT INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PLASMA THERAPY MARKET SIZE, BY JOINT INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLASMA THERAPY MARKET SIZE, BY JOINT INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PLASMA THERAPY MARKET SIZE, BY JOINT INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLASMA THERAPY MARKET SIZE, BY JOINT INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PLASMA THERAPY MARKET SIZE, BY JOINT INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLASMA THERAPY MARKET SIZE, BY TENDON REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PLASMA THERAPY MARKET SIZE, BY TENDON REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLASMA THERAPY MARKET SIZE, BY TENDON REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PLASMA THERAPY MARKET SIZE, BY TENDON REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLASMA THERAPY MARKET SIZE, BY TENDON REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PLASMA THERAPY MARKET SIZE, BY TENDON REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLASMA THERAPY MARKET SIZE, BY DIABETIC ULCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PLASMA THERAPY MARKET SIZE, BY DIABETIC ULCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PLASMA THERAPY MARKET SIZE, BY DIABETIC ULCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PLASMA THERAPY MARKET SIZE, BY DIABETIC ULCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PLASMA THERAPY MARKET SIZE, BY DIABETIC ULCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PLASMA THERAPY MARKET SIZE, BY DIABETIC ULCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLASMA THERAPY MARKET SIZE, BY PRESSURE ULCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PLASMA THERAPY MARKET SIZE, BY PRESSURE ULCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PLASMA THERAPY MARKET SIZE, BY PRESSURE ULCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PLASMA THERAPY MARKET SIZE, BY PRESSURE ULCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PLASMA THERAPY MARKET SIZE, BY PRESSURE ULCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PLASMA THERAPY MARKET SIZE, BY PRESSURE ULCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PLASMA THERAPY MARKET SIZE, BY VENOUS ULCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PLASMA THERAPY MARKET SIZE, BY VENOUS ULCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PLASMA THERAPY MARKET SIZE, BY VENOUS ULCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PLASMA THERAPY MARKET SIZE, BY VENOUS ULCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PLASMA THERAPY MARKET SIZE, BY VENOUS ULCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PLASMA THERAPY MARKET SIZE, BY VENOUS ULCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PLASMA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PLASMA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PLASMA THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PLASMA THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PLASMA THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PLASMA THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PLASMA THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PLASMA THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PLASMA THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PLASMA THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PLASMA THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PLASMA THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PLASMA THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PLASMA THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PLASMA THERAPY MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PLASMA THERAPY MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PLASMA THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PLASMA THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PLASMA THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PLASMA THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PLASMA THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PLASMA THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PLASMA THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PLASMA THERAPY MARKET SIZE, BY COSMETIC PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PLASMA THERAPY MARKET SIZE, BY COSMETIC PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PLASMA THERAPY MARKET SIZE, BY COSMETIC PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PLASMA THERAPY MARKET SIZE, BY COSMETIC PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PLASMA THERAPY MARKET SIZE, BY COSMETIC PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PLASMA THERAPY MARKET SIZE, BY COSMETIC PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PLASMA THERAPY MARKET SIZE, BY DENTAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PLASMA THERAPY MARKET SIZE, BY DENTAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PLASMA THERAPY MARKET SIZE, BY DENTAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PLASMA THERAPY MARKET SIZE, BY DENTAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PLASMA THERAPY MARKET SIZE, BY DENTAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PLASMA THERAPY MARKET SIZE, BY DENTAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PLASMA THERAPY MARKET SIZE, BY MUSCULOSKELETAL INJURIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PLASMA THERAPY MARKET SIZE, BY MUSCULOSKELETAL INJURIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PLASMA THERAPY MARKET SIZE, BY MUSCULOSKELETAL INJURIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PLASMA THERAPY MARKET SIZE, BY MUSCULOSKELETAL INJURIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PLASMA THERAPY MARKET SIZE, BY MUSCULOSKELETAL INJURIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PLASMA THERAPY MARKET SIZE, BY MUSCULOSKELETAL INJURIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PLASMA THERAPY MARKET SIZE, BY OPHTHALMOLOGY PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PLASMA THERAPY MARKET SIZE, BY OPHTHALMOLOGY PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PLASMA THERAPY MARKET SIZE, BY OPHTHALMOLOGY PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PLASMA THERAPY MARKET SIZE, BY OPHTHALMOLOGY PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PLASMA THERAPY MARKET SIZE, BY OPHTHALMOLOGY PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PLASMA THERAPY MARKET SIZE, BY OPHTHALMOLOGY PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PLASMA THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PLASMA THERAPY MARKET SIZE, BY MANUFACTURER DIRECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PLASMA THERAPY MARKET SIZE, BY MANUFACTURER DIRECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PLASMA THERAPY MARKET SIZE, BY MANUFACTURER DIRECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PLASMA THERAPY MARKET SIZE, BY MANUFACTURER DIRECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PLASMA THERAPY MARKET SIZE, BY MANUFACTURER DIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PLASMA THERAPY MARKET SIZE, BY MANUFACTURER DIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PLASMA THERAPY MARKET SIZE, BY MARKETPLACE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PLASMA THERAPY MARKET SIZE, BY MARKETPLACE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PLASMA THERAPY MARKET SIZE, BY MARKETPLACE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PLASMA THERAPY MARKET SIZE, BY MARKETPLACE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PLASMA THERAPY MARKET SIZE, BY MARKETPLACE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PLASMA THERAPY MARKET SIZE, BY MARKETPLACE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PLASMA THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PLASMA THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PLASMA THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PLASMA THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PLASMA THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PLASMA THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PLASMA THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PLASMA THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS PLASMA THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS PLASMA THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS PLASMA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS PLASMA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS PLASMA THERAPY MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS PLASMA THERAPY MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA PLASMA THERAPY MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE PLASMA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE PLASMA THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE PLASMA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE PLASMA THERAPY MARKET SIZE, BY DERMATOLOGY & AESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE PLASMA THERAPY MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE PLASMA THERAPY MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE PLASMA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE PLASMA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE PLASMA THERAPY MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE PLASMA THERAPY MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE PLASMA THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE PLASMA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE PLASMA THERAPY MARKET SI